Optimal Target Low-density Lipoprotein Level for Reducing the Risk of Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Optimal Target Low-density Lipoprotein Level for Reducing the Risk of Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis

Published:2023-12-31 Issue:4 Volume:33 Page:270-277
ISSN:1226-6051
Container-title:Korean Journal of Clinical Pharmacy
language:en
Short-container-title:Korean J Clin Pharm

Author:

Jang Min-Gyo¹,Son Yeung-Eun¹,Choi Hye Duck²,Kim Junwoo³,Kim Tae-Eun¹,Shin Kwang-Hee¹

Affiliation:

1. College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Republic of Korea

2. College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea

3. Department of Family Medicine, Daegu Health College Hospital, Daegu 41422, Republic of Korea

Publisher

The Korean College of Clinical Pharmacy

Subject

General Medicine

Link

https://pdf.medrang.co.kr/KJCP/2023/033/KJCP033-04-05.pdf

Reference27 articles.

1. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

2. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary

3. The Korean Society of Lipid and Atherosclerosis (KSoLA) Committee of Clinical Practice Guideline. Korean guidelines for the management of dyslipidemia (the 5th edition). Available from https://www.lipid.or.kr/bbs/index.html?code=care&category=&gubun=&page=1&number=1281&mode=view&keyfield=&key=. Accessed October 01, 2022.

4. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

5. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease